Cargando…
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
BACKGROUND: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the cardiorenal risk in patients with type 2 diabetes (T2D). The purpose of this study is to provide an update of all large cardiovascular outcome trials (CVOTs) with SGLT-2 inhibitors to assess their ca...
Autores principales: | Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680308/ https://www.ncbi.nlm.nih.gov/pubmed/34915880 http://dx.doi.org/10.1186/s12933-021-01430-3 |
Ejemplares similares
-
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021) -
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022) -
The residual cardiorenal risk in type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021) -
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021) -
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
por: Giugliano, Dario, et al.
Publicado: (2021)